Mutations in the copper-transporter ATP7A lead to severe neurodegeneration in the mottled brindled hemizygous male (Mo Br/y ) mouse and human patients with Menkes disease. Our earlier studies demonstrated cell-type-and -stage-specific changes in ATP7A protein expression during postnatal neurodevelopment. Here we examined copper and cuproenzyme levels in Mo Br/y mice to search for compensatory responses. While all Mo Br/y neocortical subcellular fractions had decreased copper levels, the greatest decrease (8-fold) was observed in cytosol. Immunostaining for ATP7A revealed decreased levels in Mo Br/y hippocampal pyramidal and cerebellar Purkinje neurons. In contrast, an upregulation of ATP7A protein occurred in Mo Br/y endothelial cells, perhaps to compensate for a lack of copper in the neuropil. Mo Br/y astrocytes and microglia increased their physical association with the blood-brain barrier. No alterations in ATP7A levels were observed in ependymal cells, arguing for specificity in the alteration observed at the blood-brain barrier. The decreased expression of ATP7A protein in Mo Br/y Purkinje cells was associated with impaired synaptogenesis and dramatic cytoskeletal dysfunction. Immunoblotting failed to reveal any compensatory increase in levels of ATP7B. While total levels of several cuproenzymes (peptide-amidating monooxygenase, SOD1, and SOD3) were unaltered in the Mo Br/y brain, levels of amidated cholecystokinin (CCK8) and amidated pituitary adenylate cyclase-activating polypeptide (PACAP38) were reduced in a tissue-specific fashion. The compensatory changes observed in the neurovascular unit provide insight into the success of copper injections within a defined neurodevelopmental period.
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Introduction
Dietary and genetic copper deficiency indicates that copper is required for normal development and function of the nervous system (Prohaska, 2000; Shim and Harris, 2003) . Copper is a potent reductant essential for the catalytic activity of cuproenzymes such as peptidylglycine α-amidating monooxygenase, dopamine β-monooxygenase, copper-zinc superoxide dismutase and ceruloplasmin. However, reduced copper (Cu + ) reacts with hydrogen peroxide (H 2 O 2 ) to generate hydroxyl radical (OH − ), a deleterious reactive oxygen species that damages DNA, lipid and protein.
Impaired copper homeostasis is implicated in the pathogenesis of numerous neurodegenerative diseases including Alzheimer disease (Bush, 2003) , familial amyotrophic lateral sclerosis (Selverstone et al., 2005) and prion disease (Brown, 2004) . Copper transporters and chaperones have evolved to minimize free intracellular copper while ensuring delivery to specific subcellular destinations. Mice with mutations in these proteins show substantial developmental neuropathology. Mice lacking CTR1, a high-affinity plasma membrane copper transporter, do not survive beyond E8.5, exhibiting aberrant neuroepithelial layering and impaired neural tube closure (Lee et al., 2001; Kuo et al., 2001) . Genetic elimination of ATOX-1, a cytosolic copper chaperone, results in postnatal lethality due to connective tissue and nervous system dysfunction (Hamza et al., 2001) . ATOX-1 delivers copper to ATP7A, a P-type ATPase localized to the trans-Golgi network at steady state and responsible for copper delivery to secretory pathway curproenzymes (Francis et al., 1998; La Fontaine et al., 1998; Petris et al., 2000) . In neurons, ATP7A is found in axons and dendrites and its intracellular trafficking is responsive to copper and N-methyl-D-aspartate receptor activation (Schlief et al., 2005) .
Mottled mouse strains with different mutations in ATP7A display diverse phenotypes, replicating the varied clinical severity of
